NASDAQ:KNSA Kiniksa Pharmaceuticals (KNSA) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free KNSA Stock Alerts $20.08 +0.70 (+3.61%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$19.63▼$20.4050-Day Range$16.88▼$21.7452-Week Range$12.69▼$22.09Volume403,798 shsAverage Volume408,509 shsMarket Capitalization$1.42 billionP/E Ratio182.56Dividend YieldN/APrice Target$31.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Kiniksa Pharmaceuticals alerts: Email Address Kiniksa Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside54.4% Upside$31.00 Price TargetShort InterestBearish5.16% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.86Based on 4 Articles This WeekInsider TradingSelling Shares$709,929 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.04) to $0.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.95 out of 5 starsMedical Sector2257th out of 5,430 stocksPharmaceutical Preparations Industry1027th out of 2,526 stocks 3.5 Analyst's Opinion Consensus RatingKiniksa Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageKiniksa Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.16% of the outstanding shares of Kiniksa Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverKiniksa Pharmaceuticals has a short interest ratio ("days to cover") of 9.9.Change versus previous monthShort interest in Kiniksa Pharmaceuticals has recently increased by 13.40%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKiniksa Pharmaceuticals does not currently pay a dividend.Dividend GrowthKiniksa Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KNSA. Previous Next 3.3 News and Social Media Coverage News SentimentKiniksa Pharmaceuticals has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Kiniksa Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for KNSA on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat Follows3 people have added Kiniksa Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kiniksa Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $709,929.00 in company stock.Percentage Held by Insiders54.23% of the stock of Kiniksa Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions53.95% of the stock of Kiniksa Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Kiniksa Pharmaceuticals are expected to grow in the coming year, from ($0.04) to $0.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kiniksa Pharmaceuticals is 182.56, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 146.17.Price to Earnings Ratio vs. SectorThe P/E ratio of Kiniksa Pharmaceuticals is 182.56, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 262.09.Price to Book Value per Share RatioKiniksa Pharmaceuticals has a P/B Ratio of 3.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About Kiniksa Pharmaceuticals Stock (NASDAQ:KNSA)Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Read More KNSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KNSA Stock News HeadlinesApril 26, 2024 | finance.yahoo.comAnalyst Estimates: Here's What Brokers Think Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) After Its First-Quarter ReportApril 26, 2024 | americanbankingnews.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Post Q2 2024 Earnings of ($0.06) Per Share, Wedbush ForecastsMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 25, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q1 2024 Earnings Call TranscriptApril 25, 2024 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Price Target Raised to $30.00 at Evercore ISIApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amid Strong Q1 Performance and Promising Drug ProspectsApril 24, 2024 | markets.businessinsider.comCan Growing Adoption Of Arcalyst Drive KNSA Stock Up?April 24, 2024 | seekingalpha.comKiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take ShapeMay 4, 2024 | InvestorPlace (Ad)Elon’s New Device is About to Shock the WorldUsing this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” April 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Q1 2024 Earnings Call TranscriptApril 24, 2024 | finance.yahoo.comKiniksa Pharmaceuticals First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsApril 24, 2024 | americanbankingnews.comKiniksa Pharmaceuticals (NASDAQ:KNSA) Given "Outperform" Rating at WedbushApril 24, 2024 | markets.businessinsider.comBuy Rating Affirmed for Kiniksa Pharmaceuticals Amidst Growth Potential and Strong Commercial ExecutionApril 23, 2024 | seekingalpha.comKiniksa Pharmaceuticals, Ltd. 2024 Q1 - Results - Earnings Call PresentationApril 23, 2024 | msn.comKiniksa Pharmaceuticals reports mixed Q1 results; raises FY24 outlookApril 23, 2024 | markets.businessinsider.comKNSA Stock Earnings: Kiniksa Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024April 23, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Ltd (KNSA) Q1 2024 Earnings Overview: Surpasses Revenue ForecastsApril 23, 2024 | globenewswire.comKiniksa Pharmaceuticals Reports First Quarter 2024 Financial Results and Recent Portfolio ExecutionApril 20, 2024 | investing.comKiniksa Pharmaceuticals Ltd (KNSA)April 16, 2024 | globenewswire.comKiniksa Pharmaceuticals to Report First Quarter 2024 Financial Results on April 23, 2024April 2, 2024 | globenewswire.comKiniksa Pharmaceuticals Announces Development Indication for AbiprubartMarch 7, 2024 | msn.com5 Biotech Stocks With 26% Upside Potential or MoreMarch 3, 2024 | investing.comEarnings call: Kiniksa Pharmaceuticals sees robust growth in ARCALYST salesMarch 3, 2024 | wsj.comKiniksa Pharmaceuticals Ltd.March 1, 2024 | seekingalpha.comKiniksa Pharmaceuticals Ltd. (KNSA) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | finance.yahoo.comKiniksa Pharmaceuticals Full Year 2023 Earnings: Beats ExpectationsMarch 1, 2024 | finance.yahoo.comChief Medical Officer John Paolini Sells 10,156 Shares of Kiniksa Pharmaceuticals Ltd (KNSA)See More Headlines Receive KNSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kiniksa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/23/2024Today5/04/2024Next Earnings (Estimated)7/23/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:KNSA CUSIPN/A CIK1730430 Webwww.kiniksa.com Phone(781) 431-9100FaxN/AEmployees297Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$34.00 Low Stock Price Target$30.00 Potential Upside/Downside+49.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)$0.11 Trailing P/E Ratio182.56 Forward P/E RatioN/A P/E GrowthN/ANet Income$14.08 million Net Margins2.78% Pretax Margin-7.15% Return on Equity-7.26% Return on Assets-6.09% Debt Debt-to-Equity RatioN/A Current Ratio4.21 Quick Ratio3.79 Sales & Book Value Annual Sales$270.26 million Price / Sales5.25 Cash FlowN/A Price / Cash FlowN/A Book Value$6.12 per share Price / Book3.28Miscellaneous Outstanding Shares70,610,000Free Float32,320,000Market Cap$1.42 billion OptionableOptionable Beta0.32 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Sanj K. Patel (Age 55)CEO & Chairman of the Board Comp: $1.44MMr. Eben Tessari (Age 42)Senior VP & COO Comp: $643.75kDr. John F. Paolini (Age 59)Senior VP & Chief Medical Officer Comp: $753.7kMr. Mark Ragosa C.F.A. (Age 50)Senior VP & CFO Mr. Michael R. Megna CPA (Age 53)Chief Accounting Officer & Group VP of Finance Ms. Mei JangSenior VP of Technical OperationsRachel FrankAssociate Director of Investor RelationsMr. Chad MorinSenior VP & Chief Compliance OfficerMs. Madelyn Demsky Zeylikman (Age 50)SVP, General Counsel & Secretary Ms. Melissa MannoSenior VP & Chief Human Resources OfficerMore ExecutivesKey CompetitorsGyre TherapeuticsNASDAQ:GYREXencorNASDAQ:XNCRMorphicNASDAQ:MORFAkero TherapeuticsNASDAQ:AKROArcus BiosciencesNYSE:RCUSView All CompetitorsInsiders & InstitutionsEssex Investment Management Co. LLCBought 850 shares on 5/3/2024Ownership: 0.245%Hussman Strategic Advisors Inc.Bought 157,500 shares on 5/2/2024Ownership: 0.223%Nordea Investment Management ABBought 126,742 shares on 5/2/2024Ownership: 0.179%Janney Montgomery Scott LLCBought 1,940 shares on 5/1/2024Ownership: 0.038%Mirae Asset Global Investments Co. Ltd.Bought 1,153 shares on 5/1/2024Ownership: 0.030%View All Insider TransactionsView All Institutional Transactions KNSA Stock Analysis - Frequently Asked Questions Should I buy or sell Kiniksa Pharmaceuticals stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiniksa Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KNSA shares. View KNSA analyst ratings or view top-rated stocks. What is Kiniksa Pharmaceuticals' stock price target for 2024? 4 analysts have issued 12-month price objectives for Kiniksa Pharmaceuticals' stock. Their KNSA share price targets range from $30.00 to $34.00. On average, they expect the company's stock price to reach $31.00 in the next year. This suggests a possible upside of 54.4% from the stock's current price. View analysts price targets for KNSA or view top-rated stocks among Wall Street analysts. How have KNSA shares performed in 2024? Kiniksa Pharmaceuticals' stock was trading at $17.54 at the beginning of the year. Since then, KNSA stock has increased by 14.5% and is now trading at $20.08. View the best growth stocks for 2024 here. Are investors shorting Kiniksa Pharmaceuticals? Kiniksa Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,210,000 shares, an increase of 11.8% from the March 15th total of 2,870,000 shares. Based on an average daily volume of 375,600 shares, the days-to-cover ratio is currently 8.5 days. View Kiniksa Pharmaceuticals' Short Interest. When is Kiniksa Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 23rd 2024. View our KNSA earnings forecast. How were Kiniksa Pharmaceuticals' earnings last quarter? Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) issued its earnings results on Tuesday, April, 23rd. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by $0.11. The business had revenue of $79.90 million for the quarter, compared to analysts' expectations of $76.97 million. Kiniksa Pharmaceuticals had a negative trailing twelve-month return on equity of 7.26% and a net margin of 2.78%. Kiniksa Pharmaceuticals's revenue for the quarter was up 65.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.18) EPS. What ETF holds Kiniksa Pharmaceuticals' stock? Virtus LifeSci Biotech Products ETF holds 22,347 shares of KNSA stock, representing 2.28% of its portfolio. What is Sanj K. Patel's approval rating as Kiniksa Pharmaceuticals' CEO? 1 employees have rated Kiniksa Pharmaceuticals Chief Executive Officer Sanj K. Patel on Glassdoor.com. Sanj K. Patel has an approval rating of 100% among the company's employees. This puts Sanj K. Patel in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Kiniksa Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kiniksa Pharmaceuticals investors own include Exelixis (EXEL), CRISPR Therapeutics (CRSP), Pfizer (PFE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Dicerna Pharmaceuticals (DRNA), Vaxart (VXRT) and Advanced Micro Devices (AMD). When did Kiniksa Pharmaceuticals IPO? Kiniksa Pharmaceuticals (KNSA) raised $126 million in an initial public offering (IPO) on Thursday, May 24th 2018. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs and J.P. Morgan acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Kiniksa Pharmaceuticals' major shareholders? Kiniksa Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Rice Hall James & Associates LLC (0.88%), Peregrine Capital Management LLC (0.33%), Essex Investment Management Co. LLC (0.24%), Hussman Strategic Advisors Inc. (0.22%), Los Angeles Capital Management LLC (0.20%) and Nordea Investment Management AB (0.18%). Insiders that own company stock include Barry D Quart, John F Paolini, Mark Ragosa, Michael R Megna and Sanj K Patel. View institutional ownership trends. How do I buy shares of Kiniksa Pharmaceuticals? Shares of KNSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:KNSA) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersBiden to Launch “FedNOW” [Move Your Money Now]Priority GoldElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCFW: 234x GainWeiss RatingsCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kiniksa Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.